phrykt

Genprex, Inc. (GNPX): who owns it and who trades it

As of Nov 5, 2026, GNPX insiders reported 2 open-market sales worth $22 and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brent M Longnecker (Director), with $22.

Latest filing Nov 5, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, GNPX insiders reported $0 of open-market purchases and $22 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$22
2 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 14, 2026
Filed Apr 15, 2026

Purchases and sales by month

$22$22DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 14, 2026Brent M LongneckerDirectorSale8$1.23$10Form 4
Apr 14, 2026Brent M LongneckerDirectorSale10$1.23$12Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Brent M LongneckerDirector–$22Apr 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GNPX short interest

High short interest. 15.0% of GNPX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 88%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 123,259 GNPX shares were sold short, 15.0% of the shares outstanding, down 1.3% from the report before. At the average daily volume of 170,473 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

15.0%May 15Oct 3017.5%

Days to cover

1.0May 15Oct 304.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026123,25915.04%-1%170,4731.0
Oct 15, 2026124,91615.24%+29%199,9611.0
Sep 30, 202697,07211.84%+17%361,7391.0
Sep 15, 202682,74710.09%-4%34,9262.4
Aug 31, 202685,86010.47%+37%475,4051.0
Aug 14, 202662,5907.64%+70%391,0291.0
Jul 31, 202636,8840.41%-96%50,1331.0
Jul 15, 2026884,8939.78%-6%247,8593.6
Jun 30, 2026938,28710.37%-6%412,8302.3
Jun 15, 20261.00M11.09%+3%346,5822.9
May 29, 2026976,02110.79%-6%252,2643.9
May 15, 20261.03M11.44%-8%353,4732.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded GNPX

Since Nov 17, 2024, 1 member of Congress reported 4 purchases and 0 sales of GNPX. The latest was a purchase by Tim Moore on Feb 5, 2026, reported Feb 20, 2026.

Purchases 4Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Feb 5, 2026Tim Moore (R-NC)Purchase$1K–$15KSelfFeb 20, 2026Report
Dec 18, 2025Tim Moore (R-NC)Purchase$1K–$15KSelfJan 7, 2026Report
Nov 7, 2025Tim Moore (R-NC)Purchase$1K–$15KSelfDec 2, 2025Report
Oct 29, 2025Tim Moore (R-NC)Purchase$15K–$50KSelfNov 12, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Genprex company events

Genprex filed 28 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementGenprex, Inc. issued a press release announcing results from a translational analysis of patients treated with its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product. Filing
  2. Nov 4, 2026AnnouncementGenprex, Inc. issued a press release announcing that new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, will be presented at the 2026 EORTC-NCI-AACR Symposium on Molecular… Filing
  3. Oct 28, 2026AnnouncementGenprex, Inc. issued a press release announcing that research conducted under its sponsored research collaboration with Meharry Medical College will be featured at the Gerontological Society of America 2026 Annual Scientific Meeting, taking place November 4-7, 2026, in National Harbor, Maryland. Filing
  4. Oct 21, 2026AnnouncementGenprex, Inc. issued a press release highlighting new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging and supporting broader understanding of how disruption of normal biological… Filing
  5. Aug 18, 2026AnnouncementGenprex, Inc. issued a press release announcing it had entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization to initiate the manufacturing scale-up of its diabetes gene therapy program. Filing
  6. Aug 5, 2026ListingAs previously disclosed, on July 29, 2026, the Nasdaq Hearings Panel notified Genprex, Inc. that the Panel had granted the Company’s request to continue the Company’s listing on The Nasdaq Capital Market and grant an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement… Filing
  7. Aug 3, 2026AnnouncementGenprex, Inc. issued a press release announcing its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Filing
  8. Jul 30, 2026ListingThe Nasdaq Hearings Panel notified Genprex, Inc. that it has granted the Company’s request to continue the Company’s listing on The Nasdaq Capital Market and grant an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2)… Filing
  9. Jul 14, 2026AnnouncementThe Company’s investor presentation provides certain business updates, including on its oncology and diabetes gene therapy programs. Filing
  10. Jun 22, 2026AnnouncementGenprex, Inc. issued a press release in which it announced that the Canadian Intellectual Property Office has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies for the… Filing
  11. Jun 18, 2026LeadershipGenprex, Inc. Amended and Restated 2018 Equity Incentive Plan On June 18, 2026 at the 2026 Annual Meeting of Stockholders of Genprex, Inc., the Company’s stockholders approved the Company’s amended and restated 2018 Equity Incentive Plan (the “2018 Plan”, and as so amended and restated, the… Filing
  12. Jun 12, 2026ListingGenprex, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, because the Company’s common stock closed at less than $1.00 per share over the previous 30 consecutive business days and as a result is not in compliance with the $1.00 minimum bid… Filing
  13. May 26, 2026AnnouncementGenprex, Inc. issued a press release announcing that its research collaborators’ abstract was recently published at the 2026 American Society of Clinical Oncology Annual Meeting. Filing
  14. May 14, 2026AnnouncementGenprex, Inc. issued a press release announcing that its research collaborators presented positive preclinical data on the Company’s diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy Annual Meeting on May 13, 2026 in Boston, Massachusetts. Filing
  15. Apr 30, 2026AnnouncementGenprex, Inc. issued a press release in which it announced that the Israel Patent Office has granted Genprex a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. Filing
  16. Apr 28, 2026AnnouncementGenprex, Inc. issued a press release announcing that its research collaborators will present positive preclinical data on the Company’s diabetes gene therapy drug candidate at the upcoming 2026 American Society of Gene and Cell Therapy Annual Meeting, taking place May 11-15, 2026 in Boston… Filing
  17. Apr 21, 2026AnnouncementGenprex issued a press release announcing it has entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to Reqorsa® Gene Therapy (quaratusugene ozeplasmid), the Company’s lead drug candidate that… Filing
  18. Mar 18, 2026AnnouncementGenprex, Inc. issued a press release announcing that its research collaborators will present at the upcoming 2026 American Association for Cancer Research Annual Meeting being held April 17-22, 2026 in San Diego, California. Filing
  19. Feb 23, 2026AnnouncementGenprex, Inc. issued a press release in which it announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Filing
  20. Feb 10, 2026AnnouncementGenprex, Inc. issued a press release in which it announced that IP Australia, the Australian government agency responsible for administering Australia’s intellectual property rights system, has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of… Filing
  21. Jan 9, 2026AnnouncementGenprex, Inc. was formally notified that the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC determined that the Company has regained compliance with the minimum stockholders’ equity requirement of $2.5 million under the Nasdaq Listing Rule 5550(b)(1). Filing
  22. Jan 7, 2026AnnouncementGenprex issued a press release announcing clinical program updates on its diabetes gene therapy program for GPX-002, the Company’s diabetes gene therapy drug candidate, detailing recent achievements and future advancements, including the initiation of the Company’s preclinical research in Type 2… Filing
  23. Jan 6, 2026AnnouncementGenprex, Inc. issued a press release announcing positive preliminary preclinical data from the study of GPX-002 in Type 2 diabetic animal studies, which demonstrates in vivo proof-of-concept for novel diabetes gene therapy in T2D non-human primates and rejuvenated exhausted beta cells and… Filing
  24. Dec 23, 2025AnnouncementOther Items . As previously disclosed, on August 19, 2025, Genprex, Inc. received a letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for the continued listing of the… Filing
  25. Nov 26, 2025ListingAs previously disclosed, the Nasdaq Hearings Panel of the Nasdaq Stock Market, LLC had previously notified the Company on October 13, 2025 that the Panel had granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq… Filing
  26. Nov 21, 2025AnnouncementGenprex, Inc. filed a prospectus supplement dated November 21, 2025 with the Securities and Exchange Commission for the offer and sale of additional shares of its common stock, par value $0.001 per share having an aggregate offering price of up to $75 million, pursuant to that certain At the Market… Filing
  27. Nov 19, 2025AnnouncementGenprex, Inc. issued a press release announcing that the Company has added Gabrail Cancer Center in Canton, Ohio, as a new clinical trial site for the Acclaim-1 and Acclaim-3 clinical trials studying its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in lung cancer. Filing
  28. Nov 18, 2025AnnouncementGenprex, Inc. issued a press release in which it announced that the United States Patent and Trademark Office has granted Genprex a patent that covers the use of the Company’s lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with PD-L1 antibodies, such as… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Genprex financials

Questions about Genprex, Inc. (GNPX) stock

Are GNPX insiders buying or selling?

In the last 12 months, GNPX insiders reported no open-market purchases and 2 sales worth $22. The latest trade was on Apr 14, 2026. See every trade.

What is the short interest in GNPX?

As of Oct 30, 2026, 123,259 GNPX shares were sold short, 15.0% of the shares outstanding, down 1.3% from the report before. At the average daily volume of 170,473 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Have members of Congress traded GNPX?

Yes. 1 member of Congress reported 4 purchases and 0 sales of GNPX since Nov 17, 2024. The latest was reported on Feb 20, 2026. See the trades.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.